Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Dexpramipexole (also known as KNS-760704, R-(+)-Pramipexole and (R)-Pramipexole), an enantiomer of pramipexole, is a dopamine agonist of the non-ergoline class with the potential for the treatment of amyotrophic lateral sclerosis (ALS) (also known as Lou Gehrig’s disease). It continuously and significantly reduces eosinophils in peripheral blood. In studies involving human subjects, dexpramipexole—a low molecular weight, water-soluble, orally bioavailable, renally excreted drug with linear pharmacokinetics—has proven to be well tolerated. The enantiomer of pramipexole, KNS-760704, has been demonstrated to significantly protect neurons under stress and enhance mitochondrial function.
ln Vitro |
Dexpramipexole has been found to be neuroprotective and is currently being studied for the treatment of amyotrophic lateral sclerosis (ALS). Dexpramipexole reduces mitochondrial reactive oxygen species (ROS) production, inhibits activation of apoptotic pathways, and increases cell survival against various neurotoxins and beta-amyloid neurotoxicity. Dexpramipexole has much lower dopamine agonist activity than the S-(-) isomer.
|
---|---|
References |
Molecular Formula |
C10H19CL2N3S
|
---|---|
Molecular Weight |
284.2490
|
Exact Mass |
283.07
|
Elemental Analysis |
C, 42.26; H, 6.74; Cl, 24.94; N, 14.78; S, 11.28
|
CAS # |
104632-27-1
|
Related CAS # |
Pramipexole dihydrochloride; 104632-25-9; Pramipexole; 104632-26-0; Pramipexole dihydrochloride hydrate; 191217-81-9; Dexpramipexole; 104632-28-2; 908244-04-2 (HCl hydrate)
|
Appearance |
Solid powder
|
SMILES |
CCCN[C@@H]1CCC2=C(C1)SC(=N2)N.Cl.Cl
|
InChi Key |
QMNWXHSYPXQFSK-XCUBXKJBSA-N
|
InChi Code |
InChI=1S/C10H17N3S.2ClH/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H/t7-;;/m1../s1
|
Chemical Name |
(6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;dihydrochloride
|
Synonyms |
Dexpramipexole dihydrochloride; KNS-760704; KNS760704; KNS 760704; R-Pramipexole
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~100 mg/mL (~351.80 mM)
DMSO : ≥ 100 mg/mL (~351.80 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (351.80 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.5180 mL | 17.5901 mL | 35.1803 mL | |
5 mM | 0.7036 mL | 3.5180 mL | 7.0361 mL | |
10 mM | 0.3518 mL | 1.7590 mL | 3.5180 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03430596 | Completed | Drug: Trihexyphenidyl hydrochloride Drug: Pramipexole |
Extrapyramidal Syndrome C | Shanghai Mental Health Center | May 1, 2018 | Early Phase 1 |
NCT01525641 | Completed | Drug: Mirapex LA | Parkinson Disease | Boehringer Ingelheim | February 2012 | N/A |